Back to Directory
AlveoGene
South East England
Founded 2023
Inhaled lentiviral gene therapies for rare respiratory diseases
AlveoGene is a biotechnology company developing inhaled gene therapies for rare respiratory disorders.
It uses a lentiviral vector platform engineered to deliver therapeutic genes efficiently to the cells lining the airways and lungs.
Its lead programme targets alpha-1 antitrypsin deficiency, an inherited condition that causes progressive lung damage, and the platform builds on two decades of academic respiratory gene therapy research.